PPA: phenylpropanolamine hydrochloride
In November 2000, the FDA asked pharmaceutical industries to suspend the sale of PPA, which is contained in anti-flu medicine, due to a risk of cerebral hemorrage if PPA is taken.
At first, the MHLW only issued a notice to revise the drug's package insert, but in December 2000 we requested that it suspend sales and recall the products.
In accordance with our request, the MHLW instructed pharmaceutical industries to replace PPA with PSE in 2003.
As a result, the production and sale of medicine containing PPA stopped one after another.
Topics
- YAKUGAI Ombudsperson
- Tie-up Group
No Related Information
